Discontinuation of MMF in ANCA Vasculitis Receiving Rituximab
You should discontinue mycophenolate mofetil (MMF) when transitioning to rituximab for maintenance therapy in ANCA-positive vasculitis, as rituximab alone is the preferred maintenance agent and there is no evidence supporting combination therapy with MMF in this context. 1, 2
Guideline-Based Maintenance Therapy Recommendations
The 2021 ACR/Vasculitis Foundation guidelines establish a clear hierarchy for maintenance therapy after remission induction in GPA/MPA:
- Rituximab is recommended as a first-line maintenance agent following successful remission induction with either cyclophosphamide or rituximab 1, 2
- Methotrexate or azathioprine are conditionally recommended over MMF for maintenance therapy, as azathioprine demonstrated superior efficacy with lower relapse rates compared to MMF in head-to-head trials 2, 3
- MMF is explicitly positioned as a less preferred option, reserved only for patients who cannot tolerate or have contraindications to rituximab, methotrexate, or azathioprine 2, 3
Why MMF Should Be Discontinued
The evidence structure makes clear that:
- No guideline recommends combining rituximab with MMF for maintenance therapy - all recommendations present these as alternative monotherapy options (plus low-dose glucocorticoids) 1, 2
- The 2023 KDOQI commentary emphasizes that maintenance therapy consists of "either rituximab or azathioprine" with low-dose glucocorticoids, not combination immunosuppression 1
- When rituximab is used for maintenance, scheduled re-dosing protocols (typically 500-1000 mg every 6 months) are recommended without additional immunosuppressive agents 2, 3
Practical Timing Considerations
- If plasma exchange is being used concurrently, hold plasma exchange for 48-72 hours after rituximab infusion to avoid removing the antibody 1
- MMF can be discontinued at the time of rituximab initiation for maintenance therapy, as there is no transition period requiring overlap 2
- Continue low-dose glucocorticoids during the transition, as these are part of the standard maintenance regimen with rituximab 1
Important Caveats
The one exception where MMF continuation might be considered is in the specific scenario described in early observational studies where MMF or azathioprine were added to rituximab specifically to prevent formation of anti-rituximab antibodies during initial treatment courses 4. However, this practice is not endorsed by current guidelines and scheduled rituximab dosing without additional immunosuppression is now standard 2, 3.
Monitoring After Discontinuation
When transitioning from MMF to rituximab maintenance:
- Monitor serum immunoglobulins every 6 months during rituximab therapy 1
- Continue Pneumocystis jirovecii pneumonia (PJP) prophylaxis with trimethoprim/sulfamethoxazole throughout rituximab maintenance 1
- Use scheduled rituximab re-dosing rather than ANCA titers or CD19+ B cell counts to guide timing, as flares can occur despite B-cell depletion or negative ANCA 2, 3